Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 04/28 10:14:59 pm
97 USD   -3.69%
10:46pDJGilead Reports Drop in Hepatitis C Drug Revenue
10:18p GILEAD SCIENCES : 1Q profit tumbles on slower hepatitis C drug sales
10:04p GILEAD SCIENCES : Announces Second Quarter 2016 Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Reports Drop in Hepatitis C Drug Revenue

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2016 | 10:46pm CEST

Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations.

Shares in the company slid 5.3% in after-hours trading.

The Foster City, Calif., biopharmaceutical company dominates the market for treating hepatitis C, inflammation of the liver that doesn't always show symptoms. The contagious disease affects about 3.5 million people in the U.S., according to the Centers for Disease Control and Prevention.

In the first quarter, Gilead said sales of Harvoni, its newer treatment, fell 16% to $3.02 billion. Analysts were looking for $3.15 billion, according to FactSet. Meanwhile, Sovaldi sales jumped 31%, to $1.27 billion, but the increase fell short of expectations amid soft European markets. Analysts had projected a 34% rise in Sovaldi sales to $1.30 billion.

Gilead is facing growing competition in the booming hepatitis space. During the quarter, pharmaceutical giant Merck & Co. launched a new treatment that costs 30% less than rival drugs and comes in the form of a once-daily pill. Meanwhile, AbbVie Inc. markets Viekira Pak, a competing and similarly costly treatment it launched in late 2014.

Gilead has managed to protect its market share, but analysts have cautioned that pressure is heating up. "People are worried about the hepatitis C market," said RBC analyst Michael Yoon. "Prices have gone down [and] there's increased competition," he said.

The two Hepatitis C drugs make up about two-thirds of Gilead's business. A chunk of the rest is from the company's HIV treatment, what it was originally known for.

In all for the quarter, Gilead reported a profit of $3.57 billion, or $2.53 a share, down from $4.33 billion, or $2.76 a share, a year earlier. Excluding acquisition-related expenses, stock-based compensation and other items, per-share profit rose to $3.03 from $2.94.

Total product sales rose 3.7% to $7.68 billion. Analysts projected $3.15 in adjusted earnings per share on $8.12 billion in sales, according to Thomson Reuters.

The company backed its guidance for the year, still projecting $30 billion to $31 billion in total sales.

Write to Lisa Beilfuss at lisa.beilfuss@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GILEAD SCIENCES, INC.
10:46pDJGilead Reports Drop in Hepatitis C Drug Revenue
10:18p GILEAD SCIENCES : 1Q profit tumbles on slower hepatitis C drug sales
10:14p GILEAD SCIENCES INC : Results of Operations and Financial Condition, Financial S..
10:04p GILEAD SCIENCES : Announces Second Quarter 2016 Dividend
10:02p GILEAD SCIENCES : Announces First Quarter 2016 Financial Results
09:40p GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating Broa..
02:36pDJAbbVie to Buy Cancer-Drug Maker for $5.8 Billion
04/26 GILEAD SCIENCES : secures EU approval for new HIV treatment
04/25GILEAD SCIENCES, INC. : quaterly earnings release
04/25 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead&..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials